Among children 1-23 months of age with respiratory syncytial virus-associated acute lower respiratory infection in Botswana, young age (<6 months), household use of wood as a cooking fuel, moderate or severe malnutrition and oxygen saturation <90% on room air were independent predictors of clinical nonresponse at 48 hours. Among HIV-uninfected infants less than six months of age, HIV exposure was associated with a higher risk of in-hospital mortality.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465100 | PMC |
| http://dx.doi.org/10.1097/INF.0000000000002168 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of RSVpreF vaccination on reducing the burden of respiratory syncytial virus in infants and older adults.
Nat Med
January 2025
Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, CT, USA.
Respiratory syncytial virus (RSV) causes a substantial health burden among infants and older adults. Prefusion F protein-based vaccines have shown high efficacy against RSV disease in clinical trials, offering promise for mitigating this burden through maternal and older adult immunization. Employing an individual-based model, we evaluated the impact of RSV vaccination on hospitalizations and deaths in 13 high-income countries, assuming that the vaccine does not prevent infection or transmission.
View Article and Find Full Text PDFNirsevimab decreased the subsequent risk of respiratory syncytial virus infection and wheezing in the 2023-2024 RSV season.
Pediatr Res
January 2025
Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA.
Increased respiratory syncytial virus-associated hospitalizations and ambulatory visits in very preterm infants in the first year of life following discontinuation of access to palivizumab.
Am J Perinatol
January 2025
Pediatrics, Dalhousie University, Halifax, Canada.
Background: From 2002 to 2023, palivizumab was the only intervention to reduce RSV-associated hospitalizations in high-risk infants in Canada, but advances in RSV prevention are drastically changing this landscape. Eligibility criteria for this monoclonal antibody for preterm infants varied over time across each of 10 Canadian provinces and 3 territories. The national professional pediatric association (Canadian Paediatric Society) revised its eligibility recommendations in 2015, removing access for preterm infants 30 to 32 weeks gestation (WG).
View Article and Find Full Text PDFAntibody Response to Respiratory Syncytial Virus Vaccination in Immunocompromised Persons.
JAMA
December 2024
Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
Epidemiological Characteristics of Pathogens in Bronchoalveolar Lavage Fluid in Children With Lower Respiratory Tract Infections: A Retrospective Analysis.
Pediatr Pulmonol
January 2025
Department of Pediatrics, Fu Yang People's Hospital, Fuyang, China.
Background: The COVID-19 pandemic has significantly altered the etiological spectrum and epidemiological characteristics of pediatric respiratory diseases, and a profound understanding of these changes is crucial for guiding clinical treatment. The purpose of this study is to analyze the etiological patterns and epidemiological features of pathogens in bronchoalveolar lavage fluid (BALF) from children with pediatric lower respiratory tract infections (LRTIs) after the COVID-19 pandemic, with the aim of providing effective therapeutic evidence for clinical practice.
Methods: This study enrolled pediatric patients diagnosed with LRTIs who were treated and underwent BALF pathogen detection at our hospital from June 1, 2023, to June 1, 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!